Ürotelyal Papillom ve İnverted Ürotelyal Papillom

Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, et al. Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer. 1999;86(10):2098-101

van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002;198(2):245-51.DOI: 10.1002/path.1202.

McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol. 2003;16(7):623-9.DOI: 10.1097/01.MP.0000073973.74228.1E.

Magi-Galluzzi C, Epstein JI. Urothelial papilloma of the bladder: a review of 34 de novo cases. Am J Surg Pathol. 2004;28(12):1615-20.DOI: 10.1097/00000478-200412000-00010.

Lee JH, Kim YW, Chang SG. Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol Int. 2005;74(3):268-71.DOI: 10.1159/000083561.

Al Bashir S, Yilmaz A, Gotto G, Trpkov K. Long term outcome of primary urothelial papilloma: a single institution cohort. Pathology. 2014;46(1):37-40.DOI: 10.1097/PAT.0000000000000029.

Cheng L, Montironi R, Lopez-Beltran A. TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. Eur Urol. 2017;71(3):497-8.DOI: 10.1016/j.eururo.2016.12.008.

Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification. J Urol. 2005;174(5):1976-80.DOI: 10.1097/01.ju.0000176801.16827.82.

Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16(3):187-91.DOI: 10.1097/01.MP.0000056628.38714.5D.

Alrashidy M, Atef A, Baky TA. Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder. Asian Pac J Cancer Prev. 2016;17(4):1769-72.DOI: 10.7314/apjcp.2016.17.4.1769.

Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol. 2006;59(1):83-8.DOI: 10.1136/jcp.2004.022939.

Isharwal S, Hu W, Sarungbam J, Chen YB, Gopalan A, Fine SW, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol. 2019;248(3):260-5.DOI: 10.1002/path.5261.

Lane Z, Epstein JI. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Am J Surg Pathol. 2008;32(5):758-64.DOI: 10.1097/PAS.0b013e31816092b5.

Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl. 2008(218):95-109.DOI: 10.1080/03008880802325226.

Samaratunga H, Martignoni G, Egevad L, Delahunt B. Premalignant lesions of the urinary bladder. Pathology. 2013;45(3):243-50.DOI: 10.1097/PAT.0b013e32835f6169.

Reuter VE, Algaba F, Amin MB, Cao D, Cheng L, Compérat E, et al. Urothelial Papilloma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumors of the Urinary System and Male Genital Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2016. p. 104.

Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol. 2005;36(7):741-6.DOI: 10.1016/j.humpath.2005.05.005.

Cameron KM, Lupton CH. Inverted papilloma of the lower urinary tract. Br J Urol. 1976;48(7):567-77.DOI: 10.1111/j.1464-410x.1976.tb06703.x.

Mattelaer J, Leonard A, Goddeeris P, D'Hoedt M, Van Kerrebroeck P. Inverted papilloma of bladder: clinical significance. Urology. 1988;32(3):192-7.DOI: 10.1016/0090-4295(88)90383-4.

Akgul M, MacLennan GT, Cheng L. Distinct mutational landscape of inverted urothelial papilloma. J Pathol. 2019;249(1):3-5.DOI: 10.1002/path.5307.

Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol. 2004;35(12):1499-504.DOI: 10.1016/j.humpath.2004.09.010.

Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer. 2006;107(11):2622-7.DOI: 10.1002/cncr.22311.

Kryvenko ON, Epstein JI. Mimickers of urothelial neoplasia. Ann Diagn Pathol. 2019;38:11-9.DOI: 10.1016/j.anndiagpath.2018.09.012.

MCkenney JK, Magi-Galluzzi C. Neoplasms of the Urinary Bladder. In: Zhour M, Magi-Galluzzi C, editors. Genitourinary Pathology2015. p. 192-4.

Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B, et al. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients. Urol Oncol. 2013;31(8):1584-90.DOI: 10.1016/j.urolonc.2012.03.009.

Reuter VE, Algaba F, Amin MB, Cao D, Cheng L, Compérat E, et al. Non-invasive urothelial lesions. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs2015. p. 104-5.

Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol. 2007;31(6):938-46.DOI: 10.1097/01.pas.0000249448.13466.75.

Lott S, Wang M, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol. 2009;22(5):627-32.DOI: 10.1038/modpathol.2009.28.

McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, et al. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol. 2014;45(9):1957-65.DOI: 10.1016/j.humpath.2014.06.003.

Almassi N, Pietzak EJ, Sarungbam J, Tickoo SK, Reuter VE, Solit DB, et al. Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. J Pathol. 2020;250(4):464-5.DOI: 10.1002/path.5390.